The week of June 22–28, 2026, delivered a cascade of marquee deals, striking clinical results, and regulatory milestones that underscored the accelerating globalization of China's biopharmaceutical industry.
At the top of the pile, AbbVie agreed to pay $10.9 billion in cash for Apogee Therapeutics, a bet on the immunology pipeline that follows its $2.1 billion acquisition of Capstan Therapeutics earlier this year. The Apogee deal signals that Big Pharma's appetite for autoimmune innovation remains insatiable—and that Chinese-developed platforms are increasingly in the crosshairs.
Meanwhile, Insilico Medicine, the AI-driven drug-discovery company, sealed a collaboration with SK Biopharmaceuticals worth more than $2.5 billion in potential total value, focusing on neuro-immunological diseases. It is Insilico's largest partnership to date with an Asia-Pacific partner, and a validation of machine-learning platforms that can compress years of preclinical work into months.
On the clinical front, Innovent Biologics presented Phase I/II data for IBI3003, a GPRC5D/BCMA/CD3 trispecific antibody in relapsed/refractory multiple myeloma, that stopped investors in their tracks. Among 24 patients treated at doses of 120 micrograms per kilogram or higher, the overall response rate reached 83.3%, including four complete responses and seven very good partial responses. Perhaps most striking: the drug performed comparably in patients with extramedullary disease—an 80% response rate—and in those previously treated with BCMA- or GPRC5D-targeted therapies, where it still achieved a 77.8% response rate. The pivotal Phase III trial, TriadicMM-1, has already dosed its first patient.
In a separate Phase II readout, Dayspring Pharma's CG2001 topical formulation for androgenetic alopecia increased hair density by 28.17 hairs per square centimeter at week 24, compared with 7.68 in the placebo group (p=0.006).
Capricor Therapeutics also offered encouraging long-term data from its HOPE-2 Phase III trial of Deramiocel in Duchenne muscular dystrophy. At five years post-treatment, patients showed stable cardiac function while an external control group declined by approximately 3.2%. Pulmonary function, measured by PUL 2.0 scores, decreased an average of five points over five years versus a projected decline of 2.4 points per year in untreated patients.
Deal-Making in Overdrive
The week's transaction tally reads like a survey of biopharma's hottest modalities: bispecific and trispecific T-cell engagers, antibody-drug conjugates, AI-driven discovery engines, and gene-delivery platforms.
ANTENGENE CORPORATION (Deqi Pharmaceutical, 6996.HK) licensed its CDH6×CD3 bispecific T-cell engager ATG-106 to K2 Therapeutics, a company founded by MPM BioImpact, with exclusive rights outside Greater China. The deal includes an upfront payment and near-term consideration of approximately $20 million in cash plus minority equity, with development, regulatory, and commercial milestones potentially reaching $960.5 million. An option on a second undisclosed bispecific TCE carries identical milestone potential—bringing the combined ceiling to nearly $2 billion.
Haisco Pharmaceutical Group licensed two clinical-stage small molecules to Nuvectis Pharma (NASDAQ: NVCT) for development and commercialization outside China, in a deal valued at up to $1.461 billion. The compounds target areas where Haisco has demonstrated execution: the company recently completed licensing deals with Eli Lilly and AbbVie (both in the second quarter of 2026) and posted positive Phase III results for its TKY2 inhibitor envudeucitinib in plaque psoriasis.
TrueLab Biopharmaceutical (帆礼生物) granted Bionyra Pharma exclusive global rights—outside Greater China—to two antibody candidates: TL-001, an anti-TL1A monoclonal antibody, and TL-003, an anti-TL1A/IL-23p19 bispecific antibody. The total deal value reaches up to $985 million (approximately 6.6 billion RMB), with TrueLab also securing an equity stake in Bionyra following its $165 million Series A round, led by Jeito Capital and Sofinnova Partners.
CStone Pharmaceuticals (2616.HK) granted Arrotex Pharmaceuticals, a unit of DBG Health, exclusive commercialization rights for sugamalimab (舒格利单抗) in Australia and New Zealand, covering all approved and potential future indications including Stage III/IV non-small-cell lung cancer, gastric cancer, esophageal squamous cell carcinoma, and extranodal NK/T-cell lymphoma.
And in a deal that underscores the appetite for early-stage innovation, Abbie's peer Eli Lilly expanded its research collaboration with HeYu Biopharmaceutical (和誉医药, 02256.HK), with potential milestone payments totaling up to $1.9 billion across multiple disease targets. The two companies previously struck a global collaboration and exclusive licensing agreement in 2022.
Capital Flows: From Series A to IPO Filings
Primary-market activity was equally brisk. Xihu Biopharma (西湖生物) closed a round exceeding 100 million RMB to advance its red-blood-cell drug platform—described as a world-first approach—for oncology and autoimmune indications. Investors included Shijingshan Modern Innovation Industry Fund, Ruili Synthetic Biology Fund, and existing backers Yifeng Capital, Huafang Capital, and Sequoia China.
Lyncbio Therapeutics (翎泰天润) raised nearly 100 million RMB in a Pre-A+ round just five months after its previous close, led by Boyuan Capital with follow-on from Xingze Capital. The company's lead asset, described as a world-first autoimmune ADC, has entered Phase I clinical testing.
Nanjing Leadsbiolabs Co., Ltd. (维立志博) saw its joint venture Oblenio Bio close an oversubscribed $62 million Series B led by Pfizer Ventures, with participation from Deep Track Capital, GV, and founding investor Aditum Bio. The funds will advance LBL-051, a trispecific T-cell engager, through clinical development.
Guangzhou Zhiyi Biotechnology Co., Ltd. (知易生物, ZYBio) filed for a Hong Kong main-board listing, with Guotai Junan International and Xingzheng International as joint sponsors. The company's lead asset, SK08, a live biotherapeutic product targeting irritable bowel syndrome, has entered Phase III clinical trials and could become the first approved biologic for the condition if successful.
Artivila Biopharma (科辉智药) closed a nearly 100 million RMB Series A round led by Songhe Capital to accelerate AI-driven drug discovery for neurodegenerative, autoimmune, and oncology indications. Meanwhile, lncTAC (凌泰氪生物), a pioneer in long non-coding RNA (lncRNA) therapeutics, completed consecutive Series A and A+ rounds to tackle the challenge of extrahepatic nucleic-acid drug delivery.
Regulatory Milestones: China's NMPA Delivers a Wave of Approvals
China's National Medical Products Administration approved a slate of notable therapies on June 22. Among them: CARsgen's (科济药业) chimeric antigen receptor T-cell therapy for CLDN18.2-positive, HER2-negative advanced gastric and gastroesophageal junction adenocarcinoma—the world's first approved CAR-T for a solid tumor. Sichuan Baili Tianheng Pharma's BL-B01D1, an EGFR×HER3 bispecific ADC, won approval for relapsed or metastatic nasopharyngeal carcinoma, marking the first such bispecific ADC to reach the market globally.
Eli Lilly's oral selective estrogen-receptor degrader received NMPA approval for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer—China's first oral SERD inhibitor. Johnson & Johnson's niraparib abiraterone combination gained a new indication for BRCA2-mutated metastatic hormone-sensitive prostate cancer.
In the U.S., the FDA approved Gilead's sacituzumab govitecan (Trodelvy) for two new first-line indications in triple-negative breast cancer, in combination with immune checkpoint inhibitors. Pfizer's palbociclib (Ibrance) gained a maintenance-therapy indication for HR-positive, HER2-positive metastatic breast cancer following induction chemotherapy. And AstraZeneca launched four pivotal Phase III trials for its oral small-molecule GLP-1 receptor agonist elecoglipron (AZD5004) in Type 2 diabetes.
Strategic Restructuring: Sangamo's Unwinding
In a sign of the times for capital-strained platform companies, Sangamo Therapeutics announced it would sell its gene-delivery and zinc-finger platforms, along with its prion-disease pipeline ST-506, to Eli Lilly, and its Fabry-disease gene therapy isaralgagene civaparvovec (ST-920) to Astellas. Simultaneously, Sangamo filed for voluntary Chapter 11 bankruptcy protection in Delaware, with plans to auction substantially all of its remaining assets.
The week's activity paints a clear picture: China's biopharma sector is no longer a peripheral player. From billion-dollar licensing exits to world-first regulatory approvals in solid-tumor CAR-T and bispecific ADCs, the industry is moving up the value chain—and global capital is taking notice.
Data source: Pharmacodia Weekly Selection, June 22–28, 2026. All financial figures verified against original disclosures. Currency: USD unless otherwise noted (RMB amounts converted at prevailing rates).